Compare Abeona Therapeutics Inc (ABEO) vs Vanguard Dividend Appreciation Index Fund ETF (VIG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Vanguard Dividend Appreciation Index Fund ETF trades at $237.71. The key difference: Vanguard Dividend Appreciation Index Fund ETF is trading nearer its 52-week high, Abeona Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | VIG | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | — |
52-Week High | $7.23 | $239.03 |
52-Week Low | $4.17 | $204.09 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
VIG trades at $238.88, up 0.11% with a bullish technical outlook supported by moving averages. The ETF focuses on U.S. companies with consistent dividend growth, maintaining a low 0.04% expense ratio. Recent news highlights its role in long-term wealth building through dividend compounding, though some analysts favor competitors like DGRO for momentum.
The outlook remains positive for income-focused investors seeking steady dividend growth, but risks include sector concentration in technology and competition from higher-yield alternatives. Wall Street sentiment is generally favorable, with the ETF's strategy appealing for passive income portfolios amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Vanguard Dividend Appreciation Index Fund ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →
